Loading...

Aging Demographics And Product Upgrades Will Expand Respiratory Care

Published
01 Dec 24
Updated
08 Oct 25
AnalystConsensusTarget's Fair Value
NZ$36.61
1.0% undervalued intrinsic discount
08 Oct
NZ$36.25
Loading
1Y
-2.6%
7D
-4.0%

Author's Valuation

NZ$36.611.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Oct 25
Fair value Increased 1.50%

Analysts have modestly increased their price target for Fisher & Paykel Healthcare from $36.06 to $36.61 NZD, reflecting updated forecasts for slightly higher revenue growth and improved profitability expectations. Valuation Changes Fair Value Estimate has risen slightly from NZ$36.06 to NZ$36.61 per share.

Shared on19 Sep 25
Fair value Increased 1.07%

Fisher & Paykel Healthcare's consensus revenue growth and future P/E forecasts both saw only marginal improvements, underpinning the slight increase in the analyst price target from NZ$35.68 to NZ$36.06. What's in the News Fisher & Paykel Healthcare announced an ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 4, 2025.